Autoantibody production is enhanced after mild SARS-CoV-2 infection despite vaccination in patients with and without long COVID
Visvabharathy, L.; Zhu, C.; Orban, Z. S.; Yarnoff, K.; Palacio, N.; Jimenez, M.; Lim, P.; Penaloza-MacMaster, P.; Koralnik, I. J.
Show abstract
Long COVID patients who experienced severe acute SARS-CoV-2 infection can present with humoral autoimmunity. However, whether mild SARS-CoV-2 infection increases autoantibody responses and whether vaccination can decrease autoimmunity in long COVID patients is unknown. Here, we demonstrate that mild SARS-CoV-2 infection increases autoantibodies associated with systemic lupus erythematosus (SLE) and inflammatory myopathies in long COVID patients with persistent neurologic symptoms to a greater extent than COVID convalescent controls at 8 months post-infection. Furthermore, high titers of SLE-associated autoantibodies in long COVID patients are associated with impaired cognitive performance and greater symptom severity, and subsequent vaccination/booster does not decrease autoantibody titers. In summary, we found that mild SARS-CoV-2 infection can induce persistent humoral autoimmunity in both long COVID patients and healthy COVID convalescents, suggesting that a reappraisal of vaccination and mitigation strategies is warranted.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity 95%
- Autoantigen profiling reveals a shared post-COVID signature in fully recovered and Long COVID patients 94%
- Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination 94%
Similar papers in this journal
- Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection 92%
- Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults 92%
- Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose 92%
Similar papers in this journal
- COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection 94%
- Exploratory neuroimmune profiling identifies CNS-specific alterations in COVID-19 patients with neurological involvement 93%
- Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells 93%
Similar papers in this journal
- Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19 95%
- Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and signs of neurodegeneration: a prospective cross-sectional study 94%
- SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 93%
Similar papers in this journal
- Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines 93%
- Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity 92%
- Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.